CELEX: 31994D0827
Language: en
Date: 1994-12-20 00:00:00
Title: 94/827/EC: Commission Decision of 20 December 1994 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 1995, under Council Regulation (EEC) No 594/91, as amended, on substances that deplete the ozone layer

Avis juridique important

|

31994D0827

94/827/EC: Commission Decision of 20 December 1994 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 1995, under Council Regulation (EEC) No 594/91, as amended, on substances that deplete the ozone layer  

Official Journal L 350 , 31/12/1994 P. 0126 - 0137

COMMISSION DECISION of 20 December 1994 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 1995, under Council Regulation (EEC) No 594/91, as amended, on substances that deplete the ozone layer  (94/827/EC)THE COMMISSION OF THE EUROPEAN COMMUNITIES,  Having regard to the Treaty establishing the European Community, especially Article 130s,  Having regard to Council Regulation (EEC) No 594/91 of 4 March 1991 on substances that deplete the ozone layer (1) as amended through Decision (EEC) No 3952/92 (2),  Whereas because of state of the concern for the ozone layer the Commission has decided to phase out certain controlled substances earlier than in the Montreal Protocol commencing on 1 January 1995;  Whereas Regulation (EEC) No 594/91 as amended states the Commission shall determine any essential uses which may be permitted in the Community after 31 December 1994 and any quantities of controlled substances which may be produced, placed on the market  or used for their own account by producers for these purposes;  Whereas those essential uses have to be decided for chlorofluorocarbons, as per Articles 10 (1) and 11 (1), fully halogenated chlorofluorocarbons, as per Articles 10 (2) and 11 (2), halons, as per Articles 10 (3) and 11 (3), carbon tetrachloride, as per  Articles 10 (4) and 11 (4) of Regulation (EEC) No 594/91;  Whereas the criteria applied to assessing essential uses are in line with Decision IV/25 of the Fourth Meeting of the Parties to the Montreal Protocol and are:  (a) that a use of a controlled substance should qualify as 'essential' only if:  (i) it is necessary for the health, safety or is critical for the functioning of society (encompassing cultural and intellectual aspects); and (ii) there are no available technically and economically feasible alternatives or substitutes that are acceptable from the standpoint of environment and health;  (b) that production and consumption, if any, of a controlled substance for essential uses should be permitted only if:  (i) all economically feasible steps have been taken to minimize the essential use and associated emission of the controlled substance; and (ii) the controlled substance is not available in sufficient quantity and quality from existing stocks of banked or recycled controlled substances, also bearing in mind the developing countries' need for controlled substances;  Whereas the Commission has published Decision 94/563/EC (3) on the quantities of controlled substances allowed for essential uses in the Community determined on the basis of limited applications from Member States which were considered to meet the  essential use criteria in line with the above mentioned Montreal Protocol Decision IV/25;  Whereas the Commission has published a notice to users in the European Community of controlled substances allowed for essential uses in the Community in 1995 (4) regarding Council Regulation (EEC) No 594/91, as amended, and has thereby received  applications for quantities of controlled substances for essential uses for 1995;  Whereas in the framework of the Montreal Protocol nomination and assessment procedures for essential uses, Parties are requested to identify those users who may take advantage of those essential uses in 1995;  Whereas the Council's common position of the 8 June 1994 on the Commission Proposal COM(93) 202 final (5) foresees in Articles 3, 4 and 7 a procedure whereby the requirements for essential uses can be met accordingly and the Commission shall issue  licences to those users identified, according to Article 7, and in accordance with the Committee procedure set out in Article 12 of Regulation (EEC) No 594/91;  Whereas in order to meet those essential laboratory uses identified in Decision 94/563/EC, the Commission shall identify those distributors who may supply the controlled substances for this purpose;  Whereas consequently under this framework a producer may be authorized by the competent authority of the Member State in which its relevant production is situated, to produce the controlled substances for the purpose of meeting the licensed demands  presented by the identified users, and that the competent authority of the Member State concerned shall in turn notify the Commission well in advance of any such authorization;  Whereas the identified essential uses fall into four categories, notably: medical uses, solvent uses, laboratory uses and other uses; whereas the quantitatively most important essential use is the medical use of MDIs for the treatment of asthma and  other chronic obstructive diseases, as endorsed by the UNEP Technology and Economic Assessment Panel (TEAP) in their March 1994 recommendations to the Parties of the Montreal Protocol;  Whereas Article 12 of Regulation (EEC) No 594/91 sets out the procedure according to which decisions can be taken concerning the implementation of the Regulation;  Whereas the measures provided for in this Decision are in accordance with the opinion of the Committee referred to in Article 12 of the same Regulation;  Whereas the list of essential uses and the quantities of the controlled substances are hereby given in Annex for the information of producer and user industries,  HAS ADOPTED THIS DECISION:   Article 1  Those companies who may take advantage of those essential uses for their own account in 1995 are presented in Annex 2. The allocation of essential use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115, the other fully halogenated  chlorofluorocarbons, halons and carbon tetrachloride during the period 1 January to 31 December 1995 shall be as indicated in the Annex 3 (6) hereto.   Article 2  Those companies who may take advantage of the essential uses exemption for laboratory uses, as specified in Decision 94/563/EC.   Article 3  1. This Decision is addressed to the companies listed in Annex 1.  2. This Decision shall apply as follows:  Control period: from 1 January 1995 to 31 December 1995.  Done at Brussels, 20 December 1994.  For the Commission Yannis PALEOKRASSAS Member of the Commission  (1) OJ No L 67, 14. 3. 1991, p. 1.  (2) OJ No L 405, 31. 12. 1992, p. 41.  (3) OJ No L 215, 20. 8. 1994, p. 21.  (4) OJ No C 253, 10. 9. 1994, p. 4.  (5) OJ No C 301, 27. 10. 1994, p. 1.  (6) Annex 3 is not published because it contains commercially sensitive information.     PARARTIMA ANEXO 1 / BILAG 1 / ANHANG 1 /  1 / ANNEX 1 / ANNEXE 1 / ALLEGATO 1 / BIJLAGE 1 / ANEXO 1  3M Health Care Ltd Mr. A.J. Maynard 3M House Morley Street Loughborough GB-Leicestershire LE11 1EP Akzo Nobel Chemicals BV De Heer J. Boon Welplaatweg 12 NL-3197 KS Rotterdam Laboratorio Aldo-Unión SA Dr. José Sabater Sanmarti Angel Guimerà no 123-125 E-08950 Esplugues de Llobregat (Barcelona) Sigma Aldrich Company Ltd.  Dr. C. D. Hewitt Tjheoed Brickyard New Road Gillingham GB-Dorset SP&  4JL Alcan Deutschland GmbH Herrn T. Rohling Werk Goettingen Hannoversche Strasse 1 D-37075 Goettingen Laboratorio Astra España Dr. E. Cabré Matas Mestre Joan Corrales, 95-105 E-08950 Esplugues de Llobregat (Barcelona) Albermale PPC Monsieur P. Soreau 95, rue Général de Gaulle BP 116 F-68802 Thann Cedex Ausimont SpA Dr. E. Giannetti Viale Lombardia, 20 I-20021 Bollate (MI) Bespak PLC Mr. M.A. Talbot Bergen Way Kings Lynn GB-Norfolk PE30 2JJ Bie &  Bernstsen A/S Fr. Merete Hermann Sandkabaekvej 7 DK-2610 Roedovre Boehringer Ingelheim GmbH Herrn Dr. Zimmer D-55216 Ingelheim/Rhein Caffaro SpA Dr. M. Cagnoni Via Friuli, 55 I-20031 Cesano Maderno Carlo Erba Reactifs Monsieur J.M. Ervay BP 616 Chaussée du Vexin Parc d'affaires des Portes F-27106 Val-de-Reuil Carlo Erba Reagenti Dr. R. Baschieri Via Winckelmann, 1 I-Milano DIMSO SA Stryker Implants Monsieur J. Y. Carentz Z.I. De Marticot F-33610 Cestas CCL Industries Ltd Dr. T.D. Boardman Astmoor Industrial Estate 9 Arkwright Road GB-Runcorn WA7 1NU Chiesi Farmaceutici SpA Mastre Pharma Officina Consortile Dr. P. Chiesi Via Palermo, 26/A I-43100 Parma Société Cordis Monsieur Fr. René 2905, route des Dolines F-06921 Antipolis Cedex Dideco SpA Ing. Giorgio Sgarbi Via Statale 12 Nord, 86 I-41037 Mirandola (MO) Laboratoires Domilens Madame Jacquemier 321, avenue Jean Jaurès F-69007 Lyon Elf Oil UK Ltd Mr. John Everett Environmental &  Safetey Manager Milford Haven Refinery PO Box 10 Milford Haven GB-Dyfed SA73 3JD Eurodif Production Monsieur J. N. Greffe 20, avenue de Ségur F-75302 Paris 07 SP Fiat Avio SpA Dr. F. Davico Via Nizza, 312 I-10127 Torino Fisia SpA Cenbtro Serviizi Ecologici Dott. I. Scola Strada Torino, 560 I-10043 Orbassano Fisons Scientific Equipment Mr. G. Smith Product Suppport Manager Bishop Meadow Raod Loughborough GB-Leicestershire LE11 ORG Fresenius - Smad Monsieur Ph. Castellino Directeur « Achats et logistique » Zone Industrielle de la Ponchonnière BP 0106 F-69591 L'Arbresle Cedex Fisons Plc Pharmaceutical Division Dr. K. J. Gould Derby Road 12 GB-Leicestershire LE11 OBB Fluorochem Ltd Mr. Peter Whitehead Wesley Street Old Glossop GB-Derbyshire SK13 9RY Gas-Servei, S.A.  D. L. Ma. Giralt Sans C/Motores, 151-156 nave no 9 E-08038 Barcelona G. Pohl-Boskamp GmbH &  Co.  Herrn Dr. M. Schmidt Kieler Strasse 11 D-25551 Hohenlockstedt Genzyme Phamarceuticals &  Fine Chemicals Dr. W. A. Stockburn Manufacturing Operations Manager Hollands Road Haverhill GB-Suffolk CB9 8PU Glaxo Manufacturing Services Ltd Mr. Jan Piskaldo Priory Street Ware GB-Hertfordshire SG12 ODJ Hoechst Danmark A/S Hr. R.E., Andersen Islevdalvej 110 DK-2610 Roedovre Home Office F1 Division Mr. Ch. J. Goldie Room 517 Horseferry House Dean Ryle Sq.  GB-London SW1P 2AW JGS Spruehtechnik GmbH Herrn F. Guck Im Hemmet 1 D-79664 Wehr Baden IREOS SpA Dr. G. Castiello Via Lagustena 166A I-Genova Ismar Chemica Srl Dr. Fabio de Paz Via Isocorte, 16 I-16164 Genova J.T. Baker BV De Heer F. Leurink Rijsterborgherweg 20 Postbus 1 NL-7400 AA Deventer Lancaster Synthesis Ltd.  Dr. M. L. Jasiewicz A Division of British Tar products Eastgate, White Land Morecambe GB-Lancashire Landesamt fuer Umweltschutz Sachsen-Anhalt Herrn J. Winkler Dezernatsleiter Reideburger Str. 47-49 D-06116 Halle Lacer S.A.  Dr. Eduardo Albors Yodli C/Sardenya 350 E-080025 Barcelona Liquid CarbonicDa Teresa Larrondo Climent Da Guadalupe Melero Romera Po. de la Castellana, 147 - 8a Planta E-28046 Madrid Luxcontrol SA Monsieur R. Manzoni BP 349 L-4004 Esch-sur-Alzette Medinov Monsieur Bregand ZI de Bapaume - BP 55 F-42312 Roanne Cedex Merck Herrn Dr. Reiner Hesse Gen/P Frankfurter Strasse 250 D-64293 Darmstadt Merck Ltd.  Mr. P.E. Wall Merck House Poole GB-Dorset BH15 1TD Miramed S.p.A.  Sig. M. Filipponi Via Morandi, 16 I-41037 Mirandola (MO) Mobil Oil Française (F) Monsieur P. H. Pesqueux BP 2 F-766330 Notre-Dame-de-Gravenchon Norton Ltd Mr. Peter Jordan IDA Industrial Park IRL-Waterford Parke-Davis &  Co. Ltd Mr Neil A. Grumbridge Usk Road Pontypool GB-Gwent NP4 OYH PCI Membrane Systems Ltd Mr. A. Eckersley Laverstoke Mill Whitchurch GB-Hants RG28 7NR Farmacia-Farmitalia Carlo Erba Dott. G. Salvi I-63100 Ascoli Piceno Pharmasol Ltd Mr. C.W. Brading North Way Walworth Industrial Estate Andover GB-Hampshire SP10 5AZ Prolabo Monsieur H. Doucerain 54, rue Roger Solengro F-94126 Fontenay-sous-Bois Cedex Promochem GmbH Herrn T. Karrer Mercatorstr. 1 D-46485 Wesel Resolution Chemicals Dr Chris Homan Wedgewood Way Stevenage GB-Hertfordshire SG1 4QT Rhône-Pulenc Chimie Monsieur J.P. Lanuit Quai Paul Doumer, 25 F-92408 Courbevoie Cedex Riedel-de Haën Herrn. Dr. C. Creutzburg Postfach 10 02 62 D-30918 Seelze Ringsted &  Semler A/S Fr. Lykke Andersen Literbuen 9 DK-2740 Skovlunde Schering-Plough Labo NV Mevrouw Ingrid Van de Poel Industriepark 30 B-2220 Heist-op-den-Berg Société SDS Monsieur Ph. Coste BP 4 Zone industrielle de Valdonne F-13124 Peypin Les laboratoires Servier Monsieur Charles VCIX 326, rue Marcellin Berthelot BP 227 F-45402 Fleury-les-Aubrais Sigma-Aldrich Chemie GmbH Frau Renate Reinhardt Geschaeftsbereich Fluka Messerschmittstr. 17 D-89231 Neu-Ulm Struers Kebo Lab A/S Fr. Lisbeth Hansen Roskildevej 16 DK-2620 Albertslund Studio Chiono S.r.l.  Sig. R. Chiono Via Ivrea, 42 I-10086 Rivarola C.SE (TO) Terumo Europe NV de Heer W. Dierick Interleuvenlaan 40 B-3001 Leuven Valeas SpA. Pharmaceuticals Dr. Virgilio Bernareggi Via Vallisneri, 10 I-20133 Milano Société Valois Monsieur O. Fourment BP G F-27110 Le Neubourg V.A.R.I. SpA Sig. Roberto Battigello Via del Pino, 10 I-22057 Olginate (CO) Vel NV de Heer R. Kennis Geldenaaksebaan, 464 B-6001 Leuven Rathburne Chemicals Dr. A.C. Mackay Cabertson Road GB-Walkerburn EH43 6AU P. Bacancos S.A. Chemical and Pharmaceutical Products CO.  Mr. A. Papadakis 21, Omonia Square GR-10431 Athens Agmartin H. Margiolis Co.  Mr. Tiniakos 80, Karaiskou Street GR-Pireaus M. Roumboulakis SA Mr Roumboulakis 30, Sokrates, Street GR-10552 Athens    ANNEX 2   A. MEDICAL USES  (i) Production of metered dose inhalers (MDI's) for the treatment of asthma and other chronic obstructive pulmonary diseases (CFC 11, CFC 12, CFC 113, CFC 114).   "(in tonnes)"" ID="1">3M (UK)> ID="2">514"> ID="1">Aldo-Union (E)> ID="2">57,2"> ID="1">Astra (E)> ID="2">17"> ID="1">Bespak (UK)> ID="2">156"> ID="1">Boehringer (D)> ID="2">825"> ID="1">CCL Industries (UK)> ID="2">591"> ID="1">Chiesi  Farmaceutics (I)> ID="2">120"> ID="1">Fisons Pharmaceuticals (UK)> ID="2">489"> ID="1">G. Pohl-Boskamp (D)> ID="2">10"> ID="1">Gas Servei (E)> ID="2">140"> ID="1">Glaxo (UK)> ID="2">3 624 "> ID="1">I.G. Spruehtechnik (D)> ID="2">174,5">  ID="1">Lacer (E)> ID="2">0,834"> ID="1">Liquid Carbonic (E)> ID="2">800"> ID="1">Norton (IR)> ID="2">667"> ID="1">Pharmasol (UK)> ID="2">6"> ID="1">Resolution Chemicals (UK)> ID="2">3"> ID="1">Schering-Plough (B)> ID="2">167"> ID="1">Servier (F)>  ID="2">124"> ID="1">Valeas (I)> ID="2">187"> ID="1">Valois (F)> ID="2">136"> ID="1">Vari (I)> ID="2">1,7"> ID="1">Total > ID="2">8 810,234"> (ii) Cleaning of medical prosthetics (CFC 113).   "(in tonnes)"" ID="1">Cordis (F)> ID="2">30"> ID="1">Dideco (I)> ID="2">10"> ID="1">Dimso-Stryker (F)> ID="2">0,75"> ID="1">Domilens (F)> ID="2">1,2"> ID="1">Fresenius-Smad (F)> ID="2">80"> ID="1">Medinov (F)> ID="2">1,4"> ID="1">Total >  ID="2">123,35"> (iii) Solvent use to prepare silicone solution for dipcoating of medical devices (CFC 113).   "(in tonnes)"" ID="1">Dideco (I)> ID="2">10"> ID="1">Terumo (B)> ID="2">13"> ID="1">Total > ID="2">23"> (iv) Diluent use for ethylene oxide in sterilization of chloramphenicol powder used in eye-ointments (CFC 12).   "(in tonnes)"" ID="1">Parke-Davis &  Co. Ltd (UK)> ID="2">0,4224"> ID="1">Total > ID="2">0,4224">  B. SOLVENT USES  B.1. CFCs:  (i) Active reagents used to develop fingerprints on paper (CFC 113).   "(in tonnes)"" ID="1">Home Office (UK)> ID="2">9"> ID="1">Total > ID="2">9"> (ii) Inert solvent use for the manufacture of reverse osmosis membrane in the manufacture of food and pharmaceutical products (CFC 113).   "(in tonnes)"" ID="1">PCI (UK)> ID="2">10"> ID="1">Total > ID="2">10"> B.2. Carbon tetrachloride (CCI4):  (i) Production of chlorinated rubber, chlorinated paraffin and as intermediate product for plant treatment preparations.  (ii) Production of chlorinated rubber.   "(in tonnes)"" ID="1">Caffaro (I)> ID="2">20"> ID="1">Total > ID="2">20"> (iii) Production of fibre optics.  (iv) Solvent use for NCI3 in chlorine production.   "(in tonnes)"" ID="1">Albermarle (F)> ID="2">20"> ID="1">Rhône-Poulenc (F)> ID="2">500"> ID="1">Total > ID="2">520"> (v) Purification and absorption distillation of chlorine.   "(in tonnes)"" ID="1">Akzo Nobel (NL)> ID="2">50"> ID="1">Total > ID="2">50"> (vi) Production of terephtaloyldichloride.   "(in tonnes)"" ID="1">Akzo Aramid (NL)> ID="2">72"> ID="1">Total > ID="2">72">  C. LABORATORY USES  C.1. CFCs  "(in tonnes)"" ID="1">Acros Chimica NV (B)> ID="2">0,425"> ID="1">Agmarin (GR)> ID="2">0,03 "> ID="1">Ausimont (I)> ID="2">0,2 "> ID="1">Bacacos P. (GR)> ID="2">0,035"> ID="1">Bie &  Bern. (DK)> ID="2">1,5 "> ID="1">Carlo Erba (F)>  ID="2">2,1 "> ID="1">Carlo Erba (I)> ID="2">6,4 "> ID="1">Fisons Sc. (UK)> ID="2">7,8 "> ID="1">Fluorochem (UK)> ID="2">0,269"> ID="1">Hoechst (DK)> ID="2">0,8 "> ID="1">J. T. Baker (NL)> ID="2">20 "> ID="1">Liquid Carbonic (E)> ID="2">25 ">  ID="1">Merck (D)> ID="2">76 "> ID="1">Merck (UK)> ID="2">12 "> ID="1">Prolabo (F)> ID="2">5 "> ID="1">Promochem (D)> ID="2">33 "> ID="1">Rathburn Chemicals (UK)> ID="2">6 "> ID="1">Riedel (D)> ID="2">16 "> ID="1">Roumboulakis M. (GR)>  ID="2">0,035"> ID="1">SDS (F)> ID="2">4 "> ID="1">Sigma-Aldrich (F)> ID="2">0,18 "> ID="1">Sigma-Aldrich (D)> ID="2">1,94 "> ID="1">Sigma-Aldrich (UK)> ID="2">2,101"> ID="1">Struers (DK)> ID="2">0,45 "> ID="1">Vel (B)> ID="2">0,02 "> ID="1">Total  > ID="2">221,3 "> (i) Use of CFC 113 in the extraction of organic compounds:  (ii) Quality testing of drying filters in refrigeration systems (CFC 113):  (iii) Research and development of alternative propellants for polyurethane hard foams (CFC 11):  (iv) Use of CFC 113 in the analysis of oil content in water:  C.2. Carbon tetrachloride  "(in tonnes)"" ID="1">Acros Chimica NV (B)> ID="2">0,3 "> ID="1">Agmartin (GR)> ID="2">0,035"> ID="1">Bacacos P. (GR)> ID="2">0,03 "> ID="1">Bie &  Bern. (DK)> ID="2">1,9 "> ID="1">Carlo Erba (F)> ID="2">6,5 "> ID="1">Carlo Erba (I)>  ID="2">20,5 "> ID="1">Fisons Pharm. (UK)> ID="2">1 "> ID="1">Fisons Sc. (UK)> ID="2">1,5 "> ID="1">J. T. Baker (NL)> ID="2">20 "> ID="1">Merck (D)> ID="2">80 "> ID="1">Merck (UK)> ID="2">23 "> ID="1">Prolabo (F)> ID="2">13,5 "> ID="1">Promochem  (D)> ID="2">3 "> ID="1">Rathburn Chemicals (UK)> ID="2">3 "> ID="1">Ringsted (DK)> ID="2">250 liters"> ID="1">Roumboulakis M. (GR)> ID="2">0,035"> ID="1">SDS (F)> ID="2">20 "> ID="1">Sigma-Aldrich (F)> ID="2">0,333"> ID="1">Sigma-Aldrich (D)>  ID="2">2,5 "> ID="1">Sigma-Aldrich (UK)> ID="2">1,6 "> ID="1">Struers (DK)> ID="2">0,4 "> ID="1">Vel (B)> ID="2">5 "> ID="1">Total > ID="2">205,033 + 250 liters"> (i) Use in water analysis:  (ii) Use in the testing of gas filters:  (iii) Use in halogenation reaction in research laboratories:  (iv) Use as standards for control of chemical products and monitoring of organic pollution of water, air, etc.:  (v) Use as an extraction agent and solvent for analysis for unforseable purposes:  (vi) Laboratory and research uses general: research on ODSs thermodynamics, thermophysics, chemistry kinetics and toxicology:   D. MISCELLANEOUS USES   "(in tonnes)"" ID="1">Eurodif Prod. (F)> ID="2">30"> ID="1">Total > ID="2">30">   PARARTIMA ANEXO 4 / BILAG 4 / ANHANG 4 /  4 / ANNEX 4 / ANNEXE 4 / ALLEGATO 4 / BIJLAGE 4 / ANEXO 4  Aldrich Chemical Company Dr. C. D. Hewitt The Old Brickyard New Road Gillingham UK-Dorset SP8 4JL Ausimont SpA Dr. E. Giannetti Viale Lombardia 20 I-20021 Bollate (MI) Bie &  Berntsen A-S Mr. Merete Hermann Sandbaekvej 7 DK-2610 Roedovre Carlo Erba Reactifs Mr. J.M. Ervay BP 616 Chaussée du Vexin Parc d'affaires des Portes F-27106 Val-de-Reuil Carlo Erba Reagenti Dr. R. Baschieri Via Winckelmann 1 I-Milano Chiesi Farmaceutici SpA Master Pharma Officina Consortile Dr. P. Chiesi Via Palermo 26/A I-43100 Parma Fiat Avio SpA Dr. F. Davico Via Nizza 312 I-10127 Torino Fisia SpA Centro Servizi Ecologici Dott. I. Scola Strada Torino 50 I-10043 Orbassano Fisons Pharmaceuticals plc Dr. K.J. Gould 12 Derby Road Loughborough Leicestershire LE11 0BB Fisons Scientific Equipment Mr. G. Smith Product Support Manager Bishop Meadow Road Loughborough Leicestershire UK - LE11 ORG Fluorochem Ltd Mr. Peter Whitehead Wesley Street Old GlossopDerbyshire SK13 9RY Hoechst Danmark A/S Mr. R. E. Andersen Islevdalvej 110 DK-2610 Roedovre IREOS SpA Dr. G. Castiello Via Lagustena 166A I-Genova Ismar Chemica SRL Dr. Fabio de Paz Via Isocorte 16 I-16164 Genova J.T. Baker BV De Heer F. Leurink Rijsterborgherweg 20 Postbus 1 NL-7400 AA Deventer Lancaster Synthesis Ltd Dr. M. L. Jasiewicz A Division of British Tar products Eastgate, White Lund Morecambe UK-Lancashire Merck Dr. Reiner Hesse,  Gen/P Frankfurter Strasse 250 D-64293 Darmstadt Merck Ltd Mr. P. E. Wall Merck House, Poole UK-Dorset BH15 1TD Miramed SpA Mr. M. Filipponi Via Morandi 16 I-41037 Mirandola (MO) Prolabo Mr. H. Doucerain 54, rue Roger Solengro F-94126 Fontenay-sous-Bois Cedex Promochem GmbH Mr. T. Karrer Mercatorstr. 51 D-46485 Wesel Riedel-de Haën Dr. C. Creutzburg Postfach 10 02 62 D-30918 Seelze Ringsted &  Semler A/S Lykke Andersen Literbuen 9 DK-2740 Skovlunde Société SDS Mr. Ph. Coste BP 4 Zone industrielle de Valdonne F-13124 Peypin Sigma-Aldrich Chemie GmbH Ms Renate Reinhardt Geschaeftsbereich Fluka Messerschmittstr. 17 D-89231 Neu-Ulm Sigma-Aldrich (F) Mr. Denis Micol F-38070 Saint-Quentin-Fallavier Struers Kebo Lab A/S Ms Lisbeth Hansen Roskildevej 16 DK-2620 Albertslund Studio Chiono SRL Mr. R. Chiono Via Ivrea 42 I-10086 Rivarola C. SE (TO) VEL NV Mr. R. Kennis Geldenaaksebaan 464 B-3001 Leuven Rathburne Chemicals Dr. A.C. Mackay Caberston Road Walkerburn Scotland EH 43 6AU J. T. Baker BV De Heer F. Leurink Rijsterborgherweg 20 Postbus 1 NL-7400 AA Deventer Sigma-Aldrich Chemie GmbH Ms Renate Reinhardt Geschaeftsbereich Fluka Messerschmittstr. 17 D-89231 Neu-Ulm Liquid Carbonic Mme Teresa Larrondo Climent/ Mme Guadeloupe Melero Romera Pso. de la Castellana, 147 - 8 a Planta E-28046 Madrid